Posts Tagged ‘anti-obesity medicines’
January 2, 2023 — On 60 Minutes last night, Lesley Stahl reported in vivid detail just how hard it is to get good obesity care in our broken system for healthcare. She had help. Two of the world’s top obesity medicine physicians – Fatima Cody Stanford and Caroline Apovian – took viewers into their clinics. Two of Apovian’s patients […]
January 1, 2023 — While some of us slept last night, the calendar rolled us into the start of a whole new year. A clean slate with new challenges and opportunities. So what lies ahead? It’s impossible to know (as our review of 2022 predictions nicely shows), but that won’t stop us from offering our best guess. In that […]
December 31, 2022 — “It’s difficult to make predictions, especially about the future.” With this anonymous piece of wisdom in mind, it still makes sense to take a moment to look back at the trends that we hoped and expected to shape the year we complete today. So here’s a narrative report card on our 2022 trend predictions. You, […]
December 30, 2022 — CNN, we’re looking at you. Your story claiming that “people with diabetes pay the price” for semaglutide use in obesity is problematic. The story falsely describes the demand for semaglutide as “a hot new weight loss fad.” That is simply wrong. Providing medical care for people who are trying to deal with the complex chronic […]
December 26, 2022 — This has been a good year in so many ways. COVID has moved into the background and people have been reconnecting. We’ve seen remarkable progress in understanding and care for obesity. Of course, we’ve hit some low points that help us to appreciate highlights even more. So here for your consideration is our short list […]
December 16, 2022 — We’re zooming toward the end of 2022, so it’s hard to resist looking back to see which of the posts on ConscienHealth you read the most. We are grateful for the smart and diverse people who take the time to read what we post here. Seeing what captures your attention teaches us a thing or […]
December 15, 2022 — If nothing else, the last few years have transformed global supply chains from an arcane business concern into something that touched everyone. Setting aside toilet paper and electronics, let’s think for about moment about a supply chain that will be a problem stretching into the coming year – the supply chain for obesity care. How […]
December 13, 2022 — The American Diabetes Association is out with their new standards of care for 2023 and at the top of the list of seven major changes is a refined focus on obesity. Changes in medical care are subtle and slow. But when you look at how it has evolved over recent years, the shift in views […]
December 10, 2022 — In a perverse way, there might be some good news in the current frothy coverage about new medicines for obesity and diabetes. We are a bit fed up with nonsense about who “deserves” access to care with drugs like semaglutide. But it does serve to highlight some of the usually hidden biases about treating obesity. […]
December 5, 2022 — Move over, Novo Nordisk and Eli Lilly. Amgen wants a piece of the action in obesity treatment. With some obvious pride of accomplishment, Amgen unveiled results from a phase 1 study of its dual action conjugate on Saturday. This new experimental drug, AMG 133, is a molecule that combines peptides to activate GLP-1 receptors (as […]